For any COVID-19 vaccination related queries, or to escalate an incident, please contact ICARS at england.swicars@nhs.net.

Please note that this service operates 9am-5pm Monday to Friday

To navigate this newsletter, please ctrl + click on the contents to take you to the contents

Contents:

- NEW: Decommissioning and pausing of inactive Covid-19 vaccines from the Vaccine Deployment Programme

**NEW: Decommissioning and Pausing of Inactive Covid-19 Vaccines from the Vaccine Deployment Programme**

In order to simplify the COVID-19 vaccine portfolio, significantly reduce operational complexity, and reduce wastage levels, a decision has been made to decommission three inactive Covid-19 vaccines from 17 August 2023.

The three vaccines, which are being decommissioned are:

- Spikevax Original (last delivered to sites January 2023)
- Comirnaty 30 Concentrate (last delivered to sites March 2023)
- Spikevax BA.1 (last delivered to sites March 2023)

Use of these vaccines has already ceased within the programme, as they have been replaced by newer variants on the recommendation of the JCVI and all stocks have now expired.

In addition, two further vaccine types will be officially paused from 17 August:

- Comirnaty BA.1 (last delivered to sites March 2023)
- Nuvaxovid (last delivered to sites May 2023)
Use of both these vaccine types has also temporarily ceased within the programme and all site level inventory has now expired.

Both vaccines will be kept in a paused status until further notice, allowing the programme to reactivate them if required.

Sites are reminded to consider the implications of the pausing of Nuvaxovid on their service provision, including changes to referral processes, with support from systems. Options are being considered regarding non-mRNA vaccines for Autumn/Winter and information will follow in due course.

**Foundry System:**

Work is currently underway to remove the three vaccine types being decommissioned from the Foundry system including Site Stock Manager and the Transfer App and this is expected to be completed by 31 August. The two paused vaccines will remain on the system but be hidden from view.

**Point of Care Systems:**

Spikevax Original has been removed from the Point of Care systems and will no longer be an option when recording a vaccination event. Comirnaty 30 Concentrate and Spikevax BA.1 will be removed before the Autumn campaign begins. Comirnaty BA.1 and Nuvaxovid will remain on the systems, while these vaccine types are in a paused state, but they are not to be used for recording vaccination events unless they are returned to use.

**Training Materials:**

Training and guidance materials relating to the three decommissioned vaccine types will be removed from the e-learning for health site. Training and guidance materials relating to the two paused vaccine types will remain available in case there is a requirement to reactivate.

**Actions sites need to take to prepare for the decommissioning and pausing of vaccines:**

**Vaccine Supply:** All sites should check they are not holding stocks of any of the five vaccine types due to be paused or decommissioned. If stock is held, please ensure this is disposed of immediately in line with your site's expired vaccine procedure, as this stock will have expired. Please ensure wastage and stock take records are updated accordingly in Foundry Site Stock Manager.

**Vaccine Stocktake:** All sites are requested to update their stocktake records, so they reflect a zero balance for all five vaccine types prior to the 17 August. It will no longer be possible to enter stocktakes for these 5 vaccine types after the 31 August.

**Patient Information Leaflets:** All sites should review their stocks of Patient Information Leaflets (PILs) and dispose of any PILs relating to these five vaccine types, using your standard processes.

**Combined Needles and Syringes:** Sites that are still holding stocks of any combined needles and syringe (CNS) products that were specifically issued with the three vaccine types being
decommissioned and that are not current in use with active vaccine types (see Appendix 1), should take one of the following actions if they cannot be used within your site:

- Offer them to other NHS or local settings providing NHS commissioned services within your ICB or region
  or
- Remove them from stock in line with local sharps exiting procedures

**Appendix 1: Table of current CNS in use within the Vaccine Deployment Programme, which must be retained:**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Admin CNS</th>
<th>Admin MO CNS</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comirnaty 10 Concentrate</td>
<td>GBUK Prosum 23g x 25mm, 1ml</td>
<td>GBUK Prosum 21g x 38mm Needle only</td>
<td>BD Discardit 23g x 25mm, 2ml</td>
</tr>
<tr>
<td>Comirnaty Bivalent BA.4-5</td>
<td>GBUK/Caina 25g x 25mm, 1ml safety CNS</td>
<td>Reliance 25g x 38mm, 1ml safety CNS</td>
<td>N/A</td>
</tr>
<tr>
<td>Comirnaty Bivalent BA.1 (paused)</td>
<td>GBUK/Caina 25g x 25mm, 1ml safety CNS</td>
<td>GBUK Prosum 21g x 38mm Needle only</td>
<td>N/A</td>
</tr>
<tr>
<td>Comirnaty 3 infant</td>
<td>GBUK/Caina 25g x 25mm, 1ml safety CNS</td>
<td>N/A</td>
<td>Griffiths and Neilsen 21g x 38mm safety CNS</td>
</tr>
<tr>
<td>Spikevax Bivalent Original BA.4-5</td>
<td>GBUK Prosum 25G x 25mm 1ml CNS</td>
<td>GBUK Prosum 23g x 38mm, 1ml CNS</td>
<td>N/A</td>
</tr>
<tr>
<td>Nuvaxovid (paused)</td>
<td>GBUK Prosum 25G x 25mm 1ml CNS</td>
<td>GBUK Prosum 23G x 38mm syringe</td>
<td>N/A</td>
</tr>
<tr>
<td>VidPrevtyn Beta</td>
<td>BD Flu+ 23g x 25mm, 1ml CNS</td>
<td>GBUK Prosum 23g x 38mm, 1ml CNS</td>
<td>GBUK Prosafe 21g x 38mm, 3ml safety CNS</td>
</tr>
</tbody>
</table>